Form 4: Natera Co-Founder Sells $3.2M in Stock via 10b5-1 Plans

Natera Co-Founder and Director Jonathan Sheena sold 14,000 shares of Natera common stock for approximately $3.2 million through pre-arranged Rule 10b5-1 trading plans.

Summary

• Jonathan Sheena, Co-Founder and Director of Natera, Inc. (NTRA), reported sales of Natera common stock.
• On November 20, 2025, 10,000 shares were sold directly at a weighted average price of $225.0816 per share, totaling approximately $2,250,816. This sale was executed pursuant to a Rule 10b5-1 trading plan adopted on December 11, 2024.
• On November 21, 2025, 2,000 shares were sold indirectly by the Caraluna 1 Trust at a weighted average price of $230.0097 per share, totaling approximately $460,019.40. This sale was executed pursuant to a Rule 10b5-1 trading plan adopted on June 7, 2024.
• Also on November 21, 2025, an additional 2,000 shares were sold indirectly by the Caraluna 2 Trust at a weighted average price of $230.0055 per share, totaling approximately $460,011. This sale was also executed pursuant to the Rule 10b5-1 trading plan adopted on June 7, 2024.
• The total number of shares sold across all transactions amounts to 14,000 shares.
• The total value of shares sold is approximately $3,170,846.40.
• Following these transactions, Jonathan Sheena directly beneficially owns 222,660 shares and indirectly owns 23,282 shares through each of the Caraluna 1 Trust and Caraluna 2 Trust.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the sales are by a co-founder and director, which can sometimes be viewed cautiously, the execution under pre-arranged Rule 10b5-1 plans mitigates immediate negative implications, suggesting planned liquidity rather than a reaction to adverse company news.

Positives

• The sales were conducted under pre-arranged Rule 10b5-1 trading plans, indicating a planned divestment strategy rather than a reaction to immediate negative news or market conditions.

Negatives

• Insider selling, even when pre-scheduled, can sometimes be perceived by the market as a lack of confidence in the company's future prospects, potentially leading to negative sentiment.

Risks

• Potential negative market perception due to insider selling, which could put downward pressure on the stock price.
• While the sales are under 10b5-1 plans, significant insider selling by a co-founder and director can still raise questions about management's long-term commitment or view of valuation.

Future Outlook

This Form 4 filing reports past transactions and does not contain forward-looking statements or guidance regarding Natera's future outlook.

Industry Context

Insider transactions are a routine part of the market, with Rule 10b5-1 plans commonly used by executives to manage personal finances while adhering to insider trading regulations. These sales by a co-founder and director of a biotechnology company like Natera are generally viewed within the context of individual financial planning rather than a direct reflection of industry-wide trends, unless part of a broader pattern of insider activity across the sector.

Related Party Transactions

• Sales of 4,000 shares were made indirectly by the Caraluna 1 Trust and Caraluna 2 Trust, for which the Reporting Person disclaims beneficial ownership but is associated with the trusts.

Stakeholder Impact

• Shareholders may interpret these insider sales as a signal, potentially leading to minor shifts in market sentiment or increased scrutiny of the company's performance and future prospects.
• No direct impact on employees, customers, suppliers, or creditors is indicated by this filing.

Key Dates

Recommendation

While insider selling can sometimes be a negative signal, these transactions were executed under pre-arranged Rule 10b5-1 plans. Such plans typically indicate a planned liquidity event for personal financial management rather than a reaction to new, adverse company information. Therefore, this filing alone does not necessarily warrant a change in investment thesis, and a 'hold' recommendation is appropriate based solely on this information.

Keywords

Natera, NTRA, Jonathan Sheena, Insider Trading, Form 4, Stock Sale, Rule 10b5-1, Director, Co-Founder